Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150763" target="_blank" >RIV/61989592:15110/14:33150763 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.3324/haematol.2014.107177" target="_blank" >http://dx.doi.org/10.3324/haematol.2014.107177</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2014.107177" target="_blank" >10.3324/haematol.2014.107177</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma
Popis výsledku v původním jazyce
We have read with great interest the results of the recently published prospective analysis of the Grupo Espa?ol de Linfomas/Trasplante Autólogo de Médula Ósea (GELTAMO) phase II trial.1 This paper may have an extraordinary impact on decision-making in clinical practice worldwide. Javier Briones and colleagues analyzed treatment efficacy of autologous stem cell transplant (ASCT) after 90Y-ibritumomab tiuxetan plus BEAM conditioning regimen in relapsed or refractory patients with diffuse large B-cell lymphoma (DLBCL). We fully agree with their statement that 90Y-ibritumomab tiuxetan is safe and its application leads to high treatment response rates and promising survival in DLBCL patients with a very poor prognosis. However, we are not sure about the treatment response evaluation and survival analyses. First, this study included 30 evaluable patients who received treatment. Three patients died during or shortly after ASCT and did not undergo the final re-staging procedures three months
Název v anglickém jazyce
Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma
Popis výsledku anglicky
We have read with great interest the results of the recently published prospective analysis of the Grupo Espa?ol de Linfomas/Trasplante Autólogo de Médula Ósea (GELTAMO) phase II trial.1 This paper may have an extraordinary impact on decision-making in clinical practice worldwide. Javier Briones and colleagues analyzed treatment efficacy of autologous stem cell transplant (ASCT) after 90Y-ibritumomab tiuxetan plus BEAM conditioning regimen in relapsed or refractory patients with diffuse large B-cell lymphoma (DLBCL). We fully agree with their statement that 90Y-ibritumomab tiuxetan is safe and its application leads to high treatment response rates and promising survival in DLBCL patients with a very poor prognosis. However, we are not sure about the treatment response evaluation and survival analyses. First, this study included 30 evaluable patients who received treatment. Three patients died during or shortly after ASCT and did not undergo the final re-staging procedures three months
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Haematologica: the hematology journal
ISSN
0390-6078
e-ISSN
—
Svazek periodika
99
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
IT - Italská republika
Počet stran výsledku
1
Strana od-do
"e108"
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—